Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Fasting triglycerides 500-1500 mg/dl~* Not on other lipid altering therapy, OR on stable lipid altering therapy~Main Exclusion Criteria:~* Type I diabetes or uncontrolled type II diabetes~* Recent cardiovascular or coronary event~* History of pancreatitis~* History or evidence of major and clinically significant diseases that would interfere with the conduct of the study or interpretation of data~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PRC-4016 (Type: EXPERIMENTAL): PRC-4016, oral administration once daily, capsule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration once daily, capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).